Workflow
dialysis machines
icon
搜索文档
Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework
Prnewswire· 2025-08-11 11:00
公司资本配置策略 - 启动初始10亿欧元股票回购计划的第一部分 规模达6亿欧元 [1] - 整个回购计划将在两年内完成 最迟于2026年4月30日前完成第一部分 [1] - 回购计划是FME Reignite战略的重要组成部分 旨在为股东重新点燃价值创造 [2] 公司财务政策 - 实施定期股票回购计划 并配合持续的分红政策 [3] - 将通过公司官网定期更新股票回购进展 [3] 行业地位与业务规模 - 是全球领先的肾脏疾病产品和服务提供商 [4] - 全球约有420万患者定期接受透析治疗 [4] - 通过3,676家透析诊所网络为全球约30万患者提供透析治疗 [4] - 是透析机和透析器等透析产品的领先供应商 [4] 公司基本信息 - 在法兰克福证券交易所(FME)和纽约证券交易所(FMS)上市 [4] - 总回购额度为两年内最高10亿欧元 [7] - 回购计划将持续至2027年8月10日 [7]
Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025
Prnewswire· 2025-08-05 11:00
BAD HOMBURG, Germany, Aug. 5, 2025 /PRNewswire/ -- "In the second quarter of 2025, we further improved our operational performance as strong organic revenue growth and double-digit operating income growth put us fully on track to deliver our full year 2025 financial outlook", said Helen Giza, Chief Executive Officer of Fresenius Medical Care AG. "Organic revenue growth of 7% was supported by all operating segments. The overall phasing of earnings in the first half of the year developed in line with our plan ...
Fresenius Medical Care presents its new research and innovation for kidney care at European Renal Association Congress 2025
Prnewswire· 2025-05-30 12:00
公司动态 - 费森尤斯医疗(FME)将在2025年6月4-7日举行的第62届欧洲肾脏协会(ERA)大会上展示肾病护理领域的最新研究和创新成果 [1] - 公司全球首席医疗官Frank Maddux表示,最新研究聚焦家庭护理、重症护理、中心血液透析(HD)和高容量血液透析滤过(HDF)三大领域 [2] - 公司医学办公室和肾脏研究所(RRI)将发布52篇涉及重症护理、液体管理、HDF及AI应用等肾病学关键领域的摘要 [2] 研究成果 - 关键研究《透析中动脉血氧饱和度不稳定性》获"透析"类别最佳摘要奖,该研究利用AI发现透析中低氧血症与睡眠呼吸暂停的潜在关联 [5] - CONVINCE试验分析显示HDF相比HD能减缓健康衰退速度,在身体认知功能、疼痛干预和社交参与方面表现更优 [5] - 液体超负荷变化研究证实透析前6个月液体管理情况与后续2年住院风险存在显著关联 [5] - 治疗时长回顾分析表明缩短血液透析时间会增加患者死亡率 [5] - 基于检索增强生成技术和OpenAI模型的创新系统可为透析患者提供个性化膳食建议 [5] 业务数据 - 全球约420万肾病患者需要定期接受透析治疗 [4] - 公司通过3675家透析诊所网络为全球约29.9万患者提供治疗服务 [4] - 公司在透析产品(如透析机和透析器)市场占据领先地位 [6] 会议安排 - 公司研究人员将在ERA大会460号展位现场讨论肾病护理领域的研究见解和临床创新 [3]
Fresenius Medical Care starts 2025 with strong organic revenue and income growth
Prnewswire· 2025-05-06 11:00
BAD HOMBURG, Germany, May 6, 2025 /PRNewswire/ -- "The results of the first quarter of 2025 once again demonstrate our continuous operational and financial progress as we are executing the third and last year of our current strategic plan," said Helen Giza, Chief Executive Officer of Fresenius Medical Care. "Revenue of both segments grew organically, and the phasing of the operating income development was in-line with our expectations. Care Enablement executed strongly against its transformation plan and fu ...